key: cord-0915835-iobr99c0 authors: Manfredi, Maddalena; Ghidini, Giulia; Ridolo, Erminia; Pizzi, Silvia title: Oral lesions postinjection of the first administration of Pfizer‐BioNTech SARS‐CoV‐2 (BNT162b2) vaccine date: 2021-05-24 journal: Oral Dis DOI: 10.1111/odi.13912 sha: 83c8f3a0a5a56b2fe239f7914320ceb98a3ecfaf doc_id: 915835 cord_uid: iobr99c0 nan A 34 year-old healthy woman, with no medical history of allergic reactions and not undergoing chronic systemic pharmacological therapies, presented with diffuse and painful oral lesions. These appeared two days after the first administration of Pfizer-BioNTech SARS-CoV-2 (BNT162b2) vaccine. She reported no fever after the shot, but mild diffuse joint pain, asthenia and local pain in the injection site. At clinical examination, diffuse ulcerative lesions on the floor of the mouth were observed, associated with oral eritema of the ventral surface and anterior area of the tongue. The lip mucosa appeared dry and inflamed, with mild signs of angular cheilitis (Figure 1a ,b). The patient also referred swelling of the lips and oral gingiva, where multiple small erosive ulcers were present (Figure 1c COVID-19 has been strongly associated with dysgeusia, but several oral manifestations have also been described in patients infected by SARS-CoV2 (Iranmanesh et al., 2021) . There is growing evidence that angiotensin-converting enzyme 2 (ACE2), the main host cell receptor of SARS-CoV-2, is highly expressed on the epithelial cells of the tongue and of the salivary glands, which may explain the development of dysgeusia: it is possible that SARS-CoV-2 can infect and replicate in oral keratinocytes and fibroblasts, causing oral manifestations (Brandão et al., 2021) . In addition, allergic reactions can also occur after vaccination, although oral side effects of systemically administered vaccines are extremely rare (Tarakji et al., 2014) . Few reports are present about BNT162b2 vaccine adverse reactions in the orofacial district (Cirillo, 2021) . Recently, a case of oral mucositis due to a hypersensitivity triggered by ChAdOx1 COVID-19 vaccination has been reported (Azzi et al., 2021) , with similar lesions to those here described. However, these two vaccines differ: ChAdOx1 consists of a nonreplicating viral vector while BNT162b2 is a m-RNA vaccine and they consist of different excipients triggering the human immune system with different pathways. Since the patient showed an important reactivity to polysorbate 80 during allergological tests with evident skin reaction and reappearance of oral signs and symptoms, it is plausible to associate the oral manifestations with the administration of the vaccine (Banerji et al., 2021) . Polysorbate 80 is used to make the m-RNA fat-soluble, and it is generally used to encapsulate the monofilament of the m-RNA, which otherwise is unstable in physiological conditions, and otherwise, it could not perform its function. It is known to be able to cause a crosslink reaction with one of the components of the BNT162b2 vaccine. The nano-particle possibly involved in the cross-link reaction with Polysorbate 80 is named Poly(ethylene glycol) (PEG), which has been proven to improve stability and immunogenicity of vaccine particles. Although different hydrogel cross-linking mechanisms are known to result in distinct network structures, it is still unknown how these various mechanisms influence biomolecule release (Lee et al., 2016) . Possible adverse reactions to PEG are already known in literature and have already been specifically indicated as a possible adverse effect to the BNT162b2 vaccine (Sellaturay et al., 2021) . The continuation of the vaccination campaign and the increasing number of doses administered could lead to an increase in reports of oral adverse reactions. Oral mucosal lesions in a COVID-19 patient: New signs or secondary manifestations? An episode of oral mucositis after the first administration of the ChAdOx1 COVID-19 vaccine mRNA vaccines to prevent COVID-19 disease and reported allergic reactions: Current evidence and suggested approach Oral lesions in patients with SARS-CoV-2 infection: Could the oral cavity be a target organ? Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology Reported orofacial adverse effects of COVID-19 vaccines: The knowns and the unknowns Oral manifestations of COVID-19 disease: A review article Effects of the poly(ethylene glycol) hydrogel crosslinking mechanism on protein release PEG-interpenetrated genipin-crosslinked dual-sensitive hydrogel/nanostructured lipid carrier compound formulation for topical drug administration Polyethylene glycol (PEG) is a cause of anaphylaxis to the Pfizer/ BioNTech mRNA COVID-19 vaccine Hepatitis B vaccination and associated oral manifestations: A non-systematic review of literature and case reports Oral mucositis in a SARS-CoV-2-infected patient: Secondary or truly associated condition? Oral Diseases Oral lesions postinjection of the first administration of Pfizer-BioNTech SARS-CoV-2 (BNT162b2) vaccine